KR101960352B1 - Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, bile resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amine and uses thereof - Google Patents
Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, bile resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amine and uses thereof Download PDFInfo
- Publication number
- KR101960352B1 KR101960352B1 KR1020170152265A KR20170152265A KR101960352B1 KR 101960352 B1 KR101960352 B1 KR 101960352B1 KR 1020170152265 A KR1020170152265 A KR 1020170152265A KR 20170152265 A KR20170152265 A KR 20170152265A KR 101960352 B1 KR101960352 B1 KR 101960352B1
- Authority
- KR
- South Korea
- Prior art keywords
- activity
- strain
- sbb07
- resistance
- lactobacillus brevis
- Prior art date
Links
- 150000001412 amines Chemical class 0.000 title claims abstract description 34
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 33
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 33
- 240000001929 Lactobacillus brevis Species 0.000 title claims abstract description 29
- 235000013957 Lactobacillus brevis Nutrition 0.000 title claims abstract description 29
- 230000000035 biogenic effect Effects 0.000 title claims abstract description 29
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 28
- 239000000758 substrate Substances 0.000 title claims abstract description 27
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 25
- 239000002253 acid Substances 0.000 title claims abstract description 19
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 18
- 235000013406 prebiotics Nutrition 0.000 title claims description 24
- 210000000941 bile Anatomy 0.000 title abstract description 12
- 235000021028 berry Nutrition 0.000 title abstract description 10
- 230000028327 secretion Effects 0.000 title abstract description 7
- 230000000694 effects Effects 0.000 title description 40
- 244000000010 microbial pathogen Species 0.000 title description 3
- 244000005700 microbiome Species 0.000 claims abstract description 41
- 239000006041 probiotic Substances 0.000 claims abstract description 29
- 235000018291 probiotics Nutrition 0.000 claims abstract description 29
- 230000000529 probiotic effect Effects 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 229940088598 enzyme Drugs 0.000 claims description 31
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 16
- 108091005804 Peptidases Proteins 0.000 claims description 16
- 239000004365 Protease Substances 0.000 claims description 16
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 16
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 claims description 16
- 108010059892 Cellulase Proteins 0.000 claims description 13
- 229940106157 cellulase Drugs 0.000 claims description 13
- 241000193755 Bacillus cereus Species 0.000 claims description 11
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 8
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 8
- 230000000844 anti-bacterial effect Effects 0.000 claims description 8
- 229960001340 histamine Drugs 0.000 claims description 8
- 229960003732 tyramine Drugs 0.000 claims description 8
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims description 7
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims description 7
- 108010051457 Acid Phosphatase Proteins 0.000 claims description 7
- 102000013563 Acid Phosphatase Human genes 0.000 claims description 7
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 7
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 7
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 7
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 7
- 108010027597 alpha-chymotrypsin Proteins 0.000 claims description 6
- 108010078777 Colistin Proteins 0.000 claims description 5
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims description 5
- 239000004098 Tetracycline Substances 0.000 claims description 5
- 229960004821 amikacin Drugs 0.000 claims description 5
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 5
- 229960000603 cefalotin Drugs 0.000 claims description 5
- 229960003405 ciprofloxacin Drugs 0.000 claims description 5
- 229940047766 co-trimoxazole Drugs 0.000 claims description 5
- 229960003346 colistin Drugs 0.000 claims description 5
- 229960000318 kanamycin Drugs 0.000 claims description 5
- 229930027917 kanamycin Natural products 0.000 claims description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 5
- 229930182823 kanamycin A Natural products 0.000 claims description 5
- 229960005287 lincomycin Drugs 0.000 claims description 5
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims description 5
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims description 5
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims description 5
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims description 5
- 230000003578 releasing effect Effects 0.000 claims description 5
- 229960005322 streptomycin Drugs 0.000 claims description 5
- 229960002180 tetracycline Drugs 0.000 claims description 5
- 229930101283 tetracycline Natural products 0.000 claims description 5
- 235000019364 tetracycline Nutrition 0.000 claims description 5
- 150000003522 tetracyclines Chemical class 0.000 claims description 5
- 229960001180 norfloxacin Drugs 0.000 claims description 4
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 abstract description 3
- 239000001963 growth medium Substances 0.000 abstract description 2
- 235000013305 food Nutrition 0.000 description 31
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 28
- 241000894006 Bacteria Species 0.000 description 26
- 239000002609 medium Substances 0.000 description 17
- 238000000855 fermentation Methods 0.000 description 14
- 230000004151 fermentation Effects 0.000 description 14
- 239000004310 lactic acid Substances 0.000 description 14
- 235000014655 lactic acid Nutrition 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000186660 Lactobacillus Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 235000021107 fermented food Nutrition 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 229940039696 lactobacillus Drugs 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 102000006995 beta-Glucosidase Human genes 0.000 description 6
- 108010047754 beta-Glucosidase Proteins 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 102000053187 Glucuronidase Human genes 0.000 description 5
- 108010060309 Glucuronidase Proteins 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- -1 etc. Chemical compound 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229920001202 Inulin Polymers 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 4
- 229940107187 fructooligosaccharide Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 4
- 229960000511 lactulose Drugs 0.000 description 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 102000004031 Carboxy-Lyases Human genes 0.000 description 3
- 108090000489 Carboxy-Lyases Proteins 0.000 description 3
- 108091000069 Cystinyl Aminopeptidase Proteins 0.000 description 3
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- 240000000851 Vaccinium corymbosum Species 0.000 description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 235000021014 blueberries Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960003722 doxycycline Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000000832 lactitol Substances 0.000 description 3
- 235000010448 lactitol Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 3
- 229960003451 lactitol Drugs 0.000 description 3
- DWHGNUUWCJZQHO-ZVDZYBSKSA-M potassium;(2s,5r,6r)-6-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2r,3z,5r)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 DWHGNUUWCJZQHO-ZVDZYBSKSA-M 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 239000000052 vinegar Substances 0.000 description 3
- 235000021419 vinegar Nutrition 0.000 description 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 241001444063 Aronia Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 101710180684 Beta-hexosaminidase Proteins 0.000 description 2
- 101710124976 Beta-hexosaminidase A Proteins 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 102000030900 Cystinyl aminopeptidase Human genes 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108010016731 PPAR gamma Proteins 0.000 description 2
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 2
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 2
- 101710081801 Protein O-GlcNAcase Proteins 0.000 description 2
- 101710199095 Putative beta-hexosaminidase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 235000019742 Vitamins premix Nutrition 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000019722 synbiotics Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- 101710081598 Beta-glucosidase 30 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- WNBCMONIPIJTSB-BGNCJLHMSA-N Cichoriin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1)c1c(O)cc2c(OC(=O)C=C2)c1 WNBCMONIPIJTSB-BGNCJLHMSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000002648 Lactobacillus brevis ATCC 367 Species 0.000 description 1
- 235000007048 Lactobacillus brevis ATCC 367 Nutrition 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 235000017848 Rubus fruticosus Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 description 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 description 1
- 102000019199 alpha-Mannosidase Human genes 0.000 description 1
- 108010012864 alpha-Mannosidase Proteins 0.000 description 1
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920006184 cellulose methylcellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- YXVFQADLFFNVDS-UHFFFAOYSA-N diammonium citrate Chemical compound [NH4+].[NH4+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O YXVFQADLFFNVDS-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000003028 enzyme activity measurement method Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- PRUSTPADOGZAML-LMXGZOGMSA-N erythromycin E Chemical compound C([C@H]1C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@@H](C)[C@@H]1O1)(C)O)CC)O[C@]21C[C@@](C)(OC)[C@@H](O)[C@H](C)O2 PRUSTPADOGZAML-LMXGZOGMSA-N 0.000 description 1
- PRUSTPADOGZAML-UHFFFAOYSA-N erythromycin E Natural products O1C2C(C)C(OC3C(C(CC(C)O3)N(C)C)O)C(C)(O)CC(C)C(=O)C(C)C(O)C(O)(C)C(CC)OC(=O)C2COC21CC(C)(OC)C(O)C(C)O2 PRUSTPADOGZAML-UHFFFAOYSA-N 0.000 description 1
- 229940093496 esculin Drugs 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- AWRMZKLXZLNBBK-UHFFFAOYSA-N esculin Natural products OC1OC(COc2cc3C=CC(=O)Oc3cc2O)C(O)C(O)C1O AWRMZKLXZLNBBK-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004642 ferric ammonium citrate Drugs 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009920 food preservation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- PWSKHLMYTZNYKO-UHFFFAOYSA-N heptane-1,7-diamine Chemical compound NCCCCCCCN PWSKHLMYTZNYKO-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000004313 iron ammonium citrate Substances 0.000 description 1
- 235000000011 iron ammonium citrate Nutrition 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical group 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 150000008495 β-glucosides Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A01N63/02—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3204—Probiotics, living bacteria to be ingested for action in the digestive tract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/121—Brevis
-
- A23Y2220/13—
-
- C12R1/24—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/24—Lactobacillus brevis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 유해 미생물에 대한 항균 활성, 항생제 내성, 항산화 활성, 효소 분비능, 내산성, 내담즙성, 내열성 및 프리바이오틱스 기질 이용능이 우수하고, 바이오제닉 아민을 생성하지 않는 베리류 발효물 유래의 락토바실러스 브레비스 SBB07 균주 및 이의 용도에 관한 것이다.The present invention relates to a bacterium which is excellent in antibacterial activity, antibiotic resistance, antioxidative activity, enzyme releasing ability, acid resistance, bacteriostatic resistance, heat resistance and prebiotic substrate availability against harmful microorganisms, Brevis SBB07 strains and uses thereof.
발효식품은 다양한 미생물의 발효 과정을 통해 만들어지는 식품으로 발효 과정에 관여하는 미생물에 따라 식품의 성분이 분해되고 새로운 물질이 합성되어 독특한 풍미를 형성하게 되며, 미생물로부터 다양한 대사산물이 생성되어 발효 식품의 영양가와 저장성을 높일 수 있다. 하지만, 발효를 통해 바이오제닉 아민과 같은 유해한 물질 또한 생성되어 최근에는 국내뿐만 아니라 국외에서도 발효식품 내의 바이오제닉 아민의 높은 함량이 인체에 해로운 수준이라고 그 위험성을 보고하고 있다. 바이오제닉 아민은 식품의 발효과정에서 흔히 아미노산 탈카르복실화 효소(amino acid decarboxylase) 생산 미생물에 의해 생성되는 물질로 바실러스 세레우스(Bacillus cereus) 및 아플라톡신(aflatoxin)과 같이 식품의 안전을 좌우하는 주요 인자 중 하나이다. 특히, 인체 내의 질소원, 호르몬 및 핵산과 같은 단백질의 전구체로서 생리 기능 조절에 관여하는 질소화합물로 체내 대사과정을 통해 균형을 이루고 있으나 과잉 섭취 시 구토, 알레르기, 혈압저하, 발암물질 등의 독성을 유발하게 된다. 사람이 섭취하게 되는 바이오제닉 아민은 식품을 통해 체내 축적되게 되며 한국인의 주요 섭취 식품인 전통 장류나 김치, 젓갈과 같은 발효식품에 높은 함량으로 존재하고 이는 발효 과정 중 발효 미생물의 아미노산, 온도, 산소 농도 및 pH와 같은 외부 환경에 의해 생성되는 것으로 알려져 있다. 하지만, 국내의 발효식품의 경우, 일부 미생물의 작용에 의해 발효가 진행되는 것이 아니라 다양한 미생물이 관여하여 발효가 이루어지기 때문에 미생물에 의해 생성되는 바이오제닉 아민의 제어는 어려운 실정이다. 따라서 국내에서는 이를 해결하기 위해 식품의 발효 과정에서 바실러스 서틸리스(Bacillus subtilis), 바실러스 리케니포미스(B. licheniformis), 사카로마이세스 세레비지애(Saccharomyces cerevisiae), 락토바실러스 플랜타룸(Lactobacillus plantarum) 등과 같은 바이오제닉 아민 비생성 및 분해 미생물을 활용해 바이오제닉 아민의 저감화를 위한 연구가 진행되고 있는 추세이다.Fermented foods are foods that are produced through the fermentation process of various microorganisms. Depending on the microorganisms involved in the fermentation process, the food components are decomposed and new substances are synthesized to form unique flavors. Various metabolites are produced from the microorganisms, The nutritional value and storage stability of the composition can be improved. However, harmful substances such as biorenic amines have also been produced through fermentation, and recently, it has been reported that the high content of biorenic amines in fermented foods is harmful to human body as well as at home and abroad. Biogenic amines are substances that are produced by microorganisms that produce amino acid decarboxylase, which is often used in the fermentation process of food. It is a major factor that affects food safety, such as Bacillus cereus and aflatoxin. It is one of the arguments. Especially, it is a precursor of proteins such as nitrogen source, hormone and nucleic acid in the body. It is a nitrogen compound that is involved in the regulation of physiological function. It is balanced through metabolic processes in the body. However, excessive intake causes toxicity such as vomiting, allergy, . Biogenic amines, which are consumed by humans, accumulate in the body through foods. They are present in high content in fermented foods such as traditional soy sauces, kimchi, and fermented foods, which are the main foods consumed by Koreans. This means that amino acids, It is known to be produced by an external environment such as concentration and pH. However, in the case of domestic fermented foods, it is difficult to control the biogenic amines produced by the microorganisms because fermentation proceeds not by the action of some microorganisms but by various microorganisms involved in fermentation. Therefore, in order to solve this problem, Bacillus subtilis , Bacillus Lee Kenny Po Ms (B. licheniformis), Saccharomyces cerevisiae ), Research is underway to reduce biogenic amines by utilizing biogenic amine non-producing and degrading microorganisms such as Lactobacillus plantarum .
유산균은 대표적인 GRAS(Generally recognized as safe) 균주로 발효식품에 존재하는 바이오제닉 아민의 생산을 저해하거나 분해하고, 발효과정에서 병원성 미생물의 증식 억제와 유기산과 단백질, 전분, 섬유소 등과 같은 분해효소를 생산함으로써 독특한 풍미와 조직감을 유지시켜줄 뿐만 아니라 체내 유용 장내 미생물로 존재하며 항암 및 혈중 콜레스테롤 저감 작용과 면역력 증진 등에 도움을 준다고 알려져 있어 의약품이나 건강기능 식품의 개발에 있어 사람의 건강에 이로운 작용을 하는 프로바이오틱스로 주목받고 있다. 프로바이오틱스는 프리바이오틱스인 락투로오스(lactulose), 락토수크로오스(lactosucrose), 올리고당(oligosaccharides), 라피노오스(raffinose), 이눌린(inulin), 스타키오스(stachyose) 등 복합다당류를 탄소원으로 사용하여 대표적인 프로바이오틱스인 바실러스(Bacillus)와 같은 고초균과 비피도박테리움(Bifidobacterium)과 락토바실러스(Lactobacillus) 속 유산균의 성장을 선택적으로 촉진시켜 주며, 인간과 동물의 장내 유해균을 제어함으로써 장내 환경을 개선시키는 역할을 한다고 보고되고 있다. 또한, PPAR-γ(peroxisome proliferator activated receptor-γ) 활성화를 통한 염증 억제 효과, 아토피성 피부염, 만성 신장질환 등에 대한 효능이 밝혀지고 있으며, 프리바이오틱스 소재를 활용한 신바이오틱스의 염증성 질환에 대한 효과, 장내 미생물 및 소화효소 활성에 미치는 영향 등과 같이 프로바이오틱스와 식품 원료로 사용가능한 프리바이오틱스를 조합하여 장내 환경을 효과적으로 개선할 수 있는 신바이오틱스에 대한 연구가 국내외에서 활발히 진행되고 있다. 특히, 국내에서도 건강에 대한 인식이 날로 증가하고 자연식품에 대한 선호나 항생제 남용으로 인한 문제 등으로 프로바이오틱스의 사용이 권장되고 있는 추세이나 대부분의 프로바이오틱스가 외국에서 수입한 생균을 원료로 사용하여 상품화되고 있기 때문에 수입대체 및 국내의 독자적 프로바이오틱스 균주의 개발과 관련 기술의 확보가 무엇보다도 중요한 시기이다.Lactic acid bacteria is a typical GRAS (Generally recognized as safe) strain that inhibits or degrades the production of biogenic amines present in fermented foods, inhibits the growth of pathogenic microorganisms during fermentation, and produces degradation enzymes such as organic acids, proteins, starch and fibrin , It is known that it maintains unique flavor and texture, and it is present as useful intestinal microorganism. It is known to help anticancer and blood cholesterol lowering function and immunity enhancement. Therefore, in the development of medicines and health functional foods, probiotics . Probiotics is a representative example of the use of complex polysaccharides such as lactulose, lactosucrose, oligosaccharides, raffinose, inulin, stachyose, etc., as prebiotics. Probiotic Bacillus Bacillus subtilis and bifidobacteria gambling, such as (Bacillus) Te Solarium (Bifidobacterium) and Lactobacillus (Lactobacillus) gives by selectively promoting the growth of the genus Lactobacillus, by controlling the intestinal harmful bacteria in humans and animals, reported to serve to improve the intestinal environment . In addition, the efficacy of PPAR-γ (peroxisome proliferator activated receptor-γ) activation inhibition of inflammation, atopic dermatitis, and chronic kidney disease has been revealed, and the efficacy of prebiotics in inflammatory diseases of synbiotics Effect on intestinal microorganism and digestive enzyme activity, and the like, which are capable of effectively improving the intestinal environment by combining probiotics and prebiotics usable as food materials, have been actively studied at home and abroad. Particularly, in Korea, the awareness of health is increasing day by day, and the use of probiotics is recommended due to the preference for natural food or the problem caused by the abuse of antibiotics, but most probiotics are commercialized using live bacteria imported from foreign countries Therefore, import substitution and development of independent probiotic strains in Korea and securing related technologies are the most important times.
따라서 본 발명에서는 블루베리 및 복분자와 같은 베리류와 베리류를 활용한 식초 및 엑기스로부터 프로바이오틱스 균주로 사용 가능한 유산균을 확보하고, 이들 분리주를 대상으로 바이오제닉 아민의 생성 여부와 항산화 및 효소 활성과 같은 다양한 기능성 효과를 검증하여 우수 균주를 선별하고 최종 선별한 유산균을 대상으로 프로바이오틱스 소재로의 활용 가능성을 검증하기 위한 연구를 진행하였다.Therefore, in the present invention, lactic acid bacteria which can be used as a probiotic strain can be obtained from vinegar and extracts using berries and berries such as blueberries and brambles, and a variety of functionalities such as production of biogenic amines and antioxidative and enzymatic activities The results of this study were as follows: 1.
한편, 한국등록특허 제1734367호는 유해 미생물에 대한 항균 활성, 항생제 내성, 항산화 활성, β-글루코시다제 및 세포외 효소 분비능이 우수하고, 바이오제닉 아민을 생성하지 않는 전통장류 유래의 락토바실러스 브레비스 SCML67 균주 및 이의 용도를 개시하고 있으며, 한국등록특허 제1734363호는 장류의 유해 미생물에 대한 항균 활성 및 세포외 효소 분비능이 있고, 바이오제닉 아민을 생성하지 않는 전통장류 유래의 바실러스 서틸리스 SCM688 균주 및 이의 용도를 개시하고 있다. 하지만, 본 발명의 유해 미생물에 대한 항균 활성, 항생제 내성, 항산화 활성, 효소 분비능, 내산성, 내담즙성, 내열성 및 프리바이오틱스 기질 이용능이 우수하고, 바이오제닉 아민을 생성하지 않는 베리류 발효물 유래의 락토바실러스 브레비스 SBB07 균주 및 이의 용도에 대해 아직까지 개시된 바가 없다.On the other hand, Korean Patent No. 1734367 discloses a lactic acid bacteria-derived Lactobacillus brevis strain which is excellent in antibacterial activity, antibiotic resistance, antioxidant activity,? -Glucosidase and extracellular enzyme secretory activity against harmful microorganisms, Korean Patent No. 1734363 discloses a SCML67 strain and its use, and Korean Patent No. 1734363 discloses a strain of Bacillus subtilis SCM688, which has antibacterial activity against extracellular harmful microorganisms and an ability to secrete an extracellular enzyme and does not produce a biogenic amine, And its use. However, the present invention is not limited to the use of a fermented product derived from a fermented vermiculate which is excellent in antimicrobial activity, antibiotic resistance, antioxidative activity, enzyme releasing ability, acid resistance, biliary properties, heat resistance and prebiotics substrate availability, The Lactobacillus brevis SBB07 strain and its use have not yet been disclosed.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명에서는 베리류 발효물에서 분리된 락토바실러스 브레비스(Lactobacillus brevis) SBB07 균주(KCCM12102P)가 유해 미생물인 바실러스 세레우스(Bacillus cereus)에 대한 항균 활성, 10종의 항생제 내성, 항산화 활성, β-갈락토시다제(β-galactosidase), 셀룰라제(cellulase), 루신 아릴아미다제(Leucine arylamidase) 계열의 프로테아제(protease), 알파-키모트립신(α-chymotrypsin) 및 산성인산가수분해효소(acid phosphatase) 분비능, 내산성, 내담즙성, 내열성 및 프리바이오틱스 기질 이용능이 우수하고, 바이오제닉 아민을 생성하지 않는 것을 확인함으로써, 본 발명을 완성하였다.The present invention has been made in view of the above needs, and it is an object of the present invention to provide an antibacterial activity against Lactobacillus brevis SBB07 strain (KCCM12102P) isolated from a fermented vermiculis, Bacillus cereus which is a harmful microorganism, 10 antibiotic resistance, antioxidant activity,? -Galactosidase, cellulase, leucine arylamidase protease,? -Chymotrypsin (? -Chymotrypsin ) And acid phosphatase releasing activity, acid resistance, bile resistance, heat resistance and prebiotics substrate availability, and does not produce a biogenic amine. Thus, the present invention has been completed.
상기 과제를 해결하기 위하여, 본 발명은 유해 미생물에 대한 항균 활성, 항생제 내성, 항산화 활성, 효소 분비능, 내산성, 내담즙성, 내열성 및 프리바이오틱스 기질 이용능이 우수하고, 바이오제닉 아민을 생성하지 않는 베리류 발효물 유래의 락토바실러스 브레비스(Lactobacillus brevis) SBB07 균주(KCCM12102P)를 제공한다.In order to solve the above-mentioned problems, the present invention provides a method for producing a biogenic amine which is excellent in antimicrobial activity against a harmful microorganism, antibiotic resistance, antioxidative activity, enzyme secretory ability, acid resistance, biliary properties, heat resistance and prebiotic substrate availability, Lactobacillus brevis SBB07 strain (KCCM12102P) derived from a fermentation product of berries is provided.
또한, 본 발명은 상기 균주 또는 이의 배양액을 유효성분으로 포함하는 유해 미생물에 대한 항균용 조성물을 제공한다.The present invention also provides an antimicrobial composition for a harmful microorganism comprising the strain or a culture solution thereof as an active ingredient.
또한, 본 발명은 상기 균주 또는 이의 배양액을 유효성분으로 포함하는 프로바이오틱 조성물을 제공한다.The present invention also provides a probiotic composition comprising the above strain or a culture thereof as an active ingredient.
본 발명에서는 베리류 발효물에서 분리한 락토바실러스 브레비스(Lactobacillus brevis) SBB07 균주가 유해 미생물의 증식을 억제하고, β-갈락토시다제(β-galactosidase), 셀룰라제(cellulase), 루신 아릴아미다제(Leucine arylamidase) 계열의 프로테아제(protease), 알파-키모트립신(α-chymotrypsin) 및 산성인산가수분해효소(acid phosphatase)를 분비하며, 항생제 내성, 항산화 활성, 내산성, 내담즙성, 내열성 및 프리바이오틱스 기질 이용능이 우수하고, 바이오제닉 아민을 생성하지 않는 것을 확인하였다. 따라서 본 발명의 락토바실러스 브레비스(Lactobacillus brevis) SBB07 균주 또는 이의 배양액을 유효성분으로 함유하는 유해세균에 대한 항균용 조성물 및 프로바이오틱 조성물에 매우 유용하게 사용될 수 있다.In the present invention, Lactobacillus brevis ( Lactobacillus < RTI ID = 0.0 > brevis SBB07 strain inhibits the proliferation of harmful microorganisms and inhibits proliferation of β-galactosidase, cellulase, leucine arylamidase protease, alpha-chymotrypsin chymotrypsin and acid phosphatase and is excellent in antibiotic resistance, antioxidant activity, acid resistance, biliary properties, heat resistance and prebiotics substrate availability, and does not produce a biogenic amine Respectively. Therefore, the present invention can be very usefully used for antibacterial compositions and probiotic compositions for harmful bacteria containing Lactobacillus brevis SBB07 strain or a culture thereof as an active ingredient.
도 1은 본 발명의 일 구현 예에 따른 선별된 5종의 락토바실러스 브레비스(Lactobacillus brevis) 분리주들의 항산화 활성을 나타낸 것이다.
도 2는 본 발명의 일 구현 예에 따른 최종 선별된 락토바실러스 브레비스(Lactobacillus brevis) SBB07 균주의 계통수 분석 결과를 나타낸 것이다.
도 3은 본 발명의 일 구현 예에 따른 최종 선별된 락토바실러스 브레비스(Lactobacillus brevis) SBB07 균주의 내산성(A), 내담즙성(B) 및 내열성(C)을 나타낸 것이다.
도 4는 본 발명의 일 구현 예에 따른 최종 선별된 락토바실러스 브레비스(Lactobacillus brevis) SBB07 균주의 프리바이오틱스 기질에 따른 이용능을 비교한 것이다.FIG. 1 shows the antioxidative activities of the five isolates of Lactobacillus brevis selected according to an embodiment of the present invention.
FIG. 2 shows the results of phylogenetic analysis of the finally selected Lactobacillus brevis strain SBB07 according to an embodiment of the present invention.
FIG. 3 shows the acid resistance (A), bile resistance (B) and heat resistance (C) of the finally selected Lactobacillus brevis strain SBB07 according to an embodiment of the present invention.
FIG. 4 is a graph comparing the usability of the finally selected Lactobacillus brevis SBB07 strain according to the prebiotics substrate according to an embodiment of the present invention.
본 발명의 목적을 달성하기 위하여, 본 발명은 유해 미생물에 대한 항균 활성, 항생제 내성, 항산화 활성, 효소 분비능, 내산성, 내담즙성, 내열성 및 프리바이오틱스 기질 이용능이 우수하고, 바이오제닉 아민을 생성하지 않는 베리류 발효물 유래의 락토바실러스 브레비스(Lactobacillus brevis) SBB07 균주(KCCM12102P)를 제공한다.In order to accomplish the object of the present invention, the present invention provides an antimicrobial activity, an antibiotic resistance, an antioxidative activity, an enzyme releasing ability, an acid resistance, a bile resistance, a heat resistance and a prebiotics substrate utilization ability of a harmful microorganism, Lactobacillus brevis SBB07 strain (KCCM12102P) derived from fermented berries is provided.
상기 락토바실러스 브레비스(Lactobacillus brevis) SBB07 균주(KCCM12102P)는 베리 발효물에서 분리하였으며, 유해 미생물인 바실러스 세레우스(Bacillus cereus)에 길항 능력을 가지며, β-갈락토시다제(β-galactosidase), 셀룰라제(cellulase), 루신 아릴아미다제(Leucine arylamidase) 계열의 프로테아제(protease), 알파-키모트립신(α-chymotrypsin) 및 산성인산가수분해효소(acid phosphatase) 분비능, 항산화 활성, 내산성, 내담즙성, 내열성 및 프리바이오틱스 기질인 갈락토올리고당(galactooligosaccharide)의 이용능이 우수하고, 바이오제닉 아민(biogenic amine)을 생성하지 않는 균주이다. 상기 락토바실러스 브레비스(Lactobacillus brevis) SBB07 균주를 한국미생물보존센터(Korean Culture Center of Microorganisms, KCCM)에 2017년 8월 23일자로 기탁하였다(기탁번호: KCCM12102P).The Lactobacillus brevis strain SBB07 (KCCM12102P) was isolated from the fermentation product of berry, and has antagonistic ability against Bacillus cereus , which is a harmful microorganism, and β-galactosidase, A protease of alpha-chymotrypsin and an acid phosphatase, an antioxidative activity, an acid resistance, a bile acid resistance, an antioxidant activity, a cellulase, a leucine arylamidase protease, It is a strain which has excellent heat resistance and availability of galactooligosaccharide which is a prebiotic substrate and does not produce biogenic amine. The Lactobacillus brevis SBB07 strain was cultured in Korean Culture Center of Microorganisms (KCCM) Deposited on August 23, 2017 (Accession No .: KCCM12102P).
본 발명의 일 구현 예에 따른 균주에서, 상기 유해 미생물은 바실러스 세레우스(Bacillus cereus)일 수 있으나, 이에 제한되지 않는다.In a strain according to an embodiment of the present invention, the harmful microorganism may be Bacillus cereus , but is not limited thereto.
본 발명의 일 구현 예에 따른 균주에서, 상기 항생제는 아미카신(amikacin), 세팔로신(cephalothin), 시프로플록사신(ciprofloxacin), 콜리스틴(colistin), 린코마이신(lincomycin), 카나마이신(kanamycin), 노르플록사신(norfloxacin), 스트렙토마이신(streptomycin), 테트라사이클린(tetracycline) 및 트리메토프림/설파메톡사졸(trimethoprim/sulfamethoxazole)일 수 있으나, 이에 제한되지 않는다.In a strain according to one embodiment of the present invention said antibiotic is selected from the group consisting of amikacin, cephalothin, ciprofloxacin, colistin, lincomycin, kanamycin, But are not limited to, norfloxacin, streptomycin, tetracycline, and trimethoprim / sulfamethoxazole.
본 발명의 일 구현 예에 따른 균주에서, 상기 효소는 에스테라아제 리파아제(esterase lipase), 루신 아릴아미다제(Leucine arylamidase), 발린 아릴아미다제(valine arylamidase) 및 시스틴 아릴아미다제(cystine arylamidase) 계열의 프로테아제(protease), 알파-키모트립신(α-chymotrypsin), 산성인산가수분해효소(acid phosphatase), 나프톨-AS-BI-포스포히드로라아제(Naphthol-AS-BI-phosphohydrolase), 베타-갈락토시다제(β-galactosidase), 베타-글루쿠로니다제(β-glucuronidase), 알파-글루코시다제(α-glucosidase), 베타-글루코시다제(β-glucuronidase) 및 N-아세틸-베타-글루코사미니다제(N-acetyl-β-glucosaminidase)일 수 있으며, 바람직하게는 β-갈락토시다제(β-galactosidase), 셀룰라제(cellulase), 루신 아릴아미다제(Leucine arylamidase) 계열의 프로테아제(protease), 알파-키모트립신(α-chymotrypsin) 및 산성인산가수분해효소(acid phosphatase)일 수 있으나, 이에 제한되지 않는다.In a strain according to an embodiment of the present invention, the enzyme is selected from the group consisting of an esterase lipase, a leucine arylamidase, a valine arylamidase, and a cystine arylamidase protease protease, alpha-chymotrypsin, acid phosphatase, Naphthol-AS-BI-phosphohydrolase, beta-galactosidase Glucuronidase, beta-glucosidase, beta-glucuronidase, alpha-glucosidase, beta-glucuronidase and N-acetyl-beta-glucosamidase. (N-acetyl-β-glucosaminidase), preferably β-galactosidase, cellulase, leucine arylamidase protease, , Alpha-chymotrypsin and acid phosphatase (acid ph osphatase). < / RTI >
본 발명의 일 구현 예에 따른 균주에서, 상기 내산성은 pH 2~5에 대한 내산성이며, 상기 내담즙성은 0.1~1%(w/v)의 담즙에 대한 내담즙성이며, 상기 내열성은 30~60℃의 온도에 대한 내열성일 수 있으나, 이에 제한되지 않는다. In the strain according to an embodiment of the present invention, the acid resistance is an acid resistance to a pH of 2 to 5, and the bile resistance is an intragastric bility of a bile of 0.1 to 1% (w / v) Lt; RTI ID = 0.0 > 60 C, < / RTI >
본 발명의 일 구현 예에 따른 균주에서, 상기 바이오제닉 아민(biogenic amine)은 히스타민(histamine) 또는 티라민(tyramine)일 수 있으나, 이에 제한되지 않는다.In a strain according to an embodiment of the present invention, the biogenic amine may be histamine or tyramine, but is not limited thereto.
본 발명의 일 구현 예에 따른 균주에서, 상기 프리바이오틱스 기질은 갈락토올리고당(galactooligosaccharide)일 수 있으나, 이에 제한되지 않는다.In a strain according to an embodiment of the present invention, the prebiotic substrate may be, but is not limited to, a galactooligosaccharide.
본 발명의 바이오제닉 아민(biogenic amine)은 미생물의 아미노산 디카복실라제 작용에 의해 아미노산으로부터 형성되며, 인체의 분해 한도를 넘어서는 바이오제닉 아민을 식품에서 섭취하는 경우에는 발진, 국소적 피부염증, 알레르기, 구토, 오심, 설사 등의 증상을 유발한다.The biogenic amine of the present invention is formed from an amino acid by the action of an amino acid decarboxylase of a microorganism. When a biogenic amine is ingested from a food in excess of the decomposition limit of the human body, the biogenic amine may cause rash, local skin inflammation, Vomiting, nausea and diarrhea.
또한, 본 발명은 상기 균주 또는 이의 배양액을 유효성분으로 포함하는 유해 미생물에 대한 항균용 조성물을 제공한다.The present invention also provides an antimicrobial composition for a harmful microorganism comprising the strain or a culture solution thereof as an active ingredient.
본 발명의 일 구현 예에 따른 항균용 조성물에서, 상기 유해 미생물은 바실러스 세레우스(Bacillus cereus)일 수 있으나, 이에 제한되지 않는다.In the antimicrobial composition according to one embodiment of the present invention, the harmful microorganism may be Bacillus cereus , but is not limited thereto.
본 발명의 일 구현 예에 따른 항균용 조성물에서, 상기 조성물은 바람직하게는 식품, 식품 첨가제, 사료 첨가제 또는 의약품 형태일 수 있고, 상기 식품은 유제품(우유, 두유, 가공우유), 발효유(액상 요구르트, 호상 요구르트), 드링크제, 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 알코올 음료 및 비타민 복합제로 구성되는 군으로부터 선택될 수 있으나, 이에 제한되지 않는다.In the antimicrobial composition according to one embodiment of the present invention, the composition may preferably be in the form of a food, a food additive, a feed additive, or a medicament, and the food includes dairy products (milk, soy milk, processed milk), fermented milk , Ice cream, soups, beverages, alcoholic beverages, and vitamins, and may be selected from the group consisting of, but not limited to, beverages, beverages, yogurts), drinks, meats, sausages, breads, chocolates, candies, snacks, confections, pizzas, It is not limited.
본 발명의 식품은 기능성 식품을 포함할 수 있는데, 본 발명의 기능성 식품에는 상기 유효성분 외에도 필요에 따라 다양한 보조성분을 추가로 함유할 수 있다. 본 발명의 기능성 식품의 경우, 비타민 A, 비타민 B1, 비타민 B2, 비타민 B3, 비타민 B6, 비타민 B12, 엽산(folic acid), 비타민 C, 비타민 D3, 비타민 E 등의 비타민류와, 구리, 칼슘, 철, 마그네슘, 칼륨, 아연 등의 미네랄 또는 유산균 등을 포함할 수 있다.The food of the present invention may contain a functional food. In the functional food of the present invention, in addition to the above-mentioned active ingredients, various auxiliary ingredients may be added as necessary. In the case of the functional food of the present invention, vitamins such as vitamin A, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, folic acid, vitamin C, vitamin D3 and vitamin E, Iron, magnesium, potassium, zinc, etc., or lactic acid bacteria.
또한, 본 발명의 기능성 식품 중, 건강음료는 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 포함할 수 있다. 향미제로는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 들 수 있다. 천연 탄수화물로는 포도당, 과당 등의 단당류, 말토스, 수크로오스 등의 이당류, 덱스트린, 사이클로덱스트린 등의 다당류, 자일리톨, 소르비톨, 에리트리톨 등의 당알코올류 등을 들 수 있다.In addition, among the functional foods of the present invention, health drinks may contain various flavors or natural carbohydrates as additional components such as ordinary beverages. Examples of the flavoring agent include natural sweetening agents such as tau martin and stevia extract, and synthetic sweetening agents such as saccharine and aspartame. Examples of natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol.
본 발명의 균주를 배양하는 단계에서 얻어지는 상기 균주 또는 이의 배양액을 식품 첨가물로 사용할 경우, 상기 균주 또는 이의 배양액을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용할 수 있으며, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효 성분의 혼합량은 그의 사용 목적에 따라 적합하게 결정될 수 있다.When the strain obtained in the step of culturing the strain of the present invention or a culture solution thereof is used as a food additive, the strain or the culture thereof may be directly added, used in combination with other food or food ingredients, . The amount of the active ingredient to be mixed can be suitably determined according to the intended use.
본 발명의 사료 첨가제는 기초사료에 일정 비율로 첨가하는 것이다. 상기 기초사료는 주성분이 옥수수, 대두박, 유청, 어분, 당밀, 소금, 비타민 프리믹스 및 미네랄 프리믹스 등으로 이루어질 수 있다. 비타민 프리믹스는 비타민 A, 비타민 D, 비타민 E, 리보프라빈 및 나이아신으로 구성될 수 있으며, 미네랄 프리믹스는 망간, 철, 아연, 칼슘, 구리, 코발트 및 셀레니늄 등으로 구성될 수 있다.The feed additive of the present invention is added to the base feed at a certain ratio. The basic diet may be composed of corn, soybean meal, whey, fish meal, molasses, salt, vitamin premix, and mineral premix. The vitamin premix can be composed of vitamin A, vitamin D, vitamin E, riboflavin and niacin, and the mineral premix can be composed of manganese, iron, zinc, calcium, copper, cobalt and selenium.
또한, 본 발명은 상기 균주 또는 이의 배양액을 유효성분으로 포함하는 프로바이오틱 조성물을 제공한다.The present invention also provides a probiotic composition comprising the above strain or a culture thereof as an active ingredient.
본 발명의 조성물은 상기 유효성분 외에 통상적인 약학적 담체 및 부형제를 추가로 포함할 수 있으며, 이러한 조성물은 통상적인 프로바이오틱 조성물 제조방법에 따라 열건조 또는 동결-건조하여 생균제 형태로 제조하여 이용할 수 있다. The composition of the present invention may further comprise conventional pharmaceutical carriers and excipients in addition to the above-mentioned active ingredients. Such compositions may be prepared by heat drying or freeze-drying according to a conventional method for producing a probiotic composition, .
상기와 같은 우수한 프로바이오틱 효과로 인해 상기 균주는 프로바이오틱 조성물 제조에 이용할 수 있으며, 특히, 우수한 효과로 인해서 다양한 프로바이오틱 조성물을 포함하는 식품, 의약품, 화장품, 건강식품 등의 제조에 이용될 수 있다.Due to the excellent probiotic effect as described above, the strain can be used for the production of a probiotic composition. In particular, the strain can be used for the production of foods, medicines, cosmetics, and health foods containing various probiotic compositions .
본 발명의 프로바이오틱 조성물이 포함되는 식품, 의약품, 화장품, 건강식품 등의 제조는 업계에서 일반적으로 실시하는 방법을 통하여 제조될 수 있다.
The manufacture of foods, medicines, cosmetics, health foods and the like containing the probiotic composition of the present invention can be manufactured by a method generally used in the industry.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited thereto.
재료 및 방법Materials and methods
1. 균주 분리 및 배양 1. Isolation and culture
프로바이오틱스 유산균으로 활용하기 위한 균주의 선별을 위해, 전라북도 순창군에서 재배된 베리류(블루베리, 복분자, 오디 및 아로니아) 생과와 베리류를 전통적으로 발효시켜 제조한 식초 및 엑기스 약 40여 종을 수집하여 균원 시료로 사용하였고, 수집한 1g의 시료를 채취하여 멸균된 0.85% NaCl용액 9㎖에 각 단계별로 희석한 후 희석액 100㎕을 락토바실러스 MRS 아가(DifcoTM, MI, USA) 배지에 도말하여 37℃에서 24시간 동안 배양하였다. 미생물의 형태적 차이를 이용하여 1차로 분리주를 선별한 후 다시 순수 배양하여 균주를 분리하였다. 분리한 미생물은 다음 연구에 사용을 위하여 -80℃에서 보관하여 사용하였다.
For the selection of strains for probiotic lactic acid bacteria, about 40 kinds of vinegar and extract prepared by fermentation of berries (blueberry, bokbunja, audi and aronia) cultivated in Sunchang - gun, 1 g of the collected sample was sampled and diluted in 9 ml of sterilized 0.85% NaCl solution at each step. 100 μl of the diluted solution was plated on Lactobacillus MRS agar (Difco ™ , MI, USA) For 24 hours. Using the morphological differences of the microorganisms, isolates were firstly selected and then cultured again to isolate the strains. The separated microorganisms were stored at -80 ° C for use in the next study.
2. 2. 세포외Extracellular 효소 활성 Enzyme activity
분리 균주의 세포외 효소들 중 프로테아제(protease) 및 셀룰라아제(cellulase)의 활성은 양 등의 방법(Yang, H. J. et al., 2016, J. Life Sci., 26, 571-583)에 따라 측정하였다. 프로테아제 분비능은 스킴 밀크(skim milk)를 기질로 선택하여 2% 스킴 밀크(DifcoTM)에 1.5% 아가를 첨가한 스킴 밀크 아가 배지를 제조하여 사용하였고, 셀룰라제 분비능은 카르복실메틸 셀룰로오스(carboxylmethyl cellulose, CMC, JUNSEI chemical Co. Ltd.)을 기질로 선택하여 1% 카르복실메틸 셀룰로오스를 함유한 CMC 아가 배지를 제조하여 사용하였다. 상기 제조된 각각의 효소 분비능 측정배지에 각 균주의 배양 상등액을 0.45μm의 시린지 필터(Sartorius, Frankfurt, Germany)로 제균한 뒤 100㎕씩을 직경 8mm의 준비한 웰(well)에 분주하여 25℃에서 24시간 동안 반응시킨 후 프로테아제 및 셀룰라제 분비능을 투명환의 직경으로 프로테아제 및 셀룰라아제 분비능을 측정하였다.The activity of protease and cellulase in the extracellular enzymes of the isolate was determined by Yang et al., (1986), J. Life Sci. 26, 571-583). Protease secretion is skim milk (skim milk) for selecting as a substrate by 2% skim milk (Difco TM) 1.5% agar a scheme was prepared by using the milk agar medium was added to, cellulase secretion is carboxymethyl cellulose (carboxylmethyl cellulose , CMC, JUNSEI chemical Co. Ltd.) was used as a substrate to prepare a CMC agar medium containing 1% of carboxymethyl cellulose. The culture supernatant of each strain was sterilized with a 0.45 μm syringe filter (Sartorius, Frankfurt, Germany), and 100 μl of each supernatant was dispensed into a well of a diameter of 8 mm, After incubation for a time, protease and cellulase secretion ability was measured by the diameter of the transparent ring and protease and cellulase secretion.
또한, 베타-글루코시다제(β-glucosidase) 효소활성을 분석하기 위해, 1.0% 에스쿨린(esculin) 및 0.5% 구연산 철 암모늄(ferric ammonium citrate)을 첨가하여 제조한 락토바실러스 MRS 아가 플레이트에 분리주를 접종하여 37℃에서 24시간 배양한 후 콜로니 주변에 생기는 검정색 투명환의 유무에 따라 베타-글루코시다제 효소활성을 조사하였다.
Further, in order to analyze the activity of β-glucosidase enzyme, a lactobacillus MRS agar plate prepared by adding 1.0% esculin and 0.5% ferric ammonium citrate was added with a separator After inoculation and incubation at 37 ° C for 24 hours, the activity of beta-glucosidase enzyme was examined according to the presence or absence of black transparent rings around the colonies.
3. 식품 부패 원인균에 대한 항균 활성3. Antimicrobial activity against food-causing bacteria
선별 균주의 식품 부패 원인균에 대한 항균 활성 측정은 병원성 세균인 바실러스 세레우스(Bacillus cereus) KCCM40935 및 KCTC3624 균주가 각각 포함되어 있는 0.8% 소프트 아가 플레이트를 제조하여 한천 확산법(Lee, J. H. et al., 2009. Food Sci. Biotechnol., 18, 959-964)에 준하여 조사하였으며 0.45㎛의 멤브레인 필터(Sartorius)로 제균한 분리주의 배양 상등액 100㎕을 각각의 항균 활성 측정 배지에 분주한 뒤 30℃에서 24시간 동안 배양하여 형성된 억제환의 크기에 따라 항균 활성의 유무를 측정하였다.
The antimicrobial activity of the selective strains against the food spoilage bacteria was determined by preparing 0.8% soft agar plates containing the pathogenic bacteria Bacillus cereus KCCM40935 and KCTC3624, respectively, and using the agar diffusion method (Lee, JH et al., 2009 100 μl of the culture supernatant from the culture supernatant which was sterilized by a membrane filter (Sartorius) of 0.45 μm was dispensed into each of the antimicrobial activity measuring media and cultured at 30 ° C. for 24 hours The presence of antimicrobial activity was measured according to the size of the inhibitory ring formed by incubation.
4. 항산화 활성 측정4. Antioxidant activity measurement
분리주에 대한 항산화 활성은 DPPH(2,2-dipheyl-1-picryl-hydrazyl, Sigma-aldrich, MO, USA)을 일부 변환하여 사용하여 측정하였다(Lee, J. H. et al., 2009. Food Sci. Biotechnol., 18, 959-964). 100μM의 DPPH 에탄올 용액 180㎕에 20㎕의 배양 상등액을 첨가한 후, 반응 산물을 30분 동안 실온에서 반응시킨 후 UV/VIS 스펙트로포토미터(SPECORD200, Analytic jena)로 517㎚에서 흡광도를 측정하여 하기식에 따라 항산화 활성을 측정하였다. 대조구로는 배양 배지만을 첨가한 실험구를 사용하여 동일하게 측정하였다.The antioxidant activity of the isolates was measured by partial conversion of DPPH (2,2-dipheyl-1-picryl-hydrazyl, Sigma-aldrich, MO, USA) (Lee, JH et al., 2009. Food Sci. Biotechnol , 18, 959-964). 20 mu l of culture supernatant was added to 180 mu l of a 100 mu M DPPH ethanol solution, the reaction product was reacted at room temperature for 30 minutes, and the absorbance at 517 nm was measured with a UV / VIS spectrophotometer (SPECORD200, Analytic jena) The antioxidant activity was measured according to the formula. As a control, the same experiment was carried out using a test tube containing a culture medium.
항산화 활성(%) = [1-(Abs517nm of sample)/(Abs517nm of control)]×100
Antioxidant activity (%) = [1- (Abs 517 nm of sample ) / (Abs 517 nm of control )] 100
5. 5. 바이오제닉Biogenic 아민Amine 생성 여부 조사 Investigation of creation
선별 분리주의 바이오제닉 아민 생성 여부 조사는 MRS 액체 배지에 각 분리주를 접종한 후, 37℃ 현탁 배양기(VS-1203P3V, Vision Scientific Co. Ltd., Daejeon, Korea)로 150 rpm에서 24시간 전배양 후, 1㎖의 전배양액을 히스타민 및 티라민 전구체 아미노산인 히스티딘 및 티로신이 0.1% 포함된 MRS 액체 배지 9㎖에 접종하고 37℃ 현탁 배양기에서 150 rpm으로 24시간 동안 본 배양하였다. 본 배양액은 13,000 rpm에서 30분간 원심분리하여 균체를 제거한 상등액을 바이오제닉 아민 분석을 위한 시료로 사용하였다. 시료 용액 및 표준 용액을 각각 0.5 ㎖ 취한 후 0.25㎖의 1,7-디아미노헵탄(1,7-diaminoheptane, Sigma-aldrich), 0.25㎖의 포화 Na2CO3 용액(Sigma-aldrich), 1% 아세톤(Sigma-aldrich) 및 0.4㎖의 댄실 클로라이드(dansyl chloride, Sigma-aldrich)을 혼합한 후 45℃에서 1시간 동안 유도체화 하였다. 유도체화 한 시료에 0.25㎖의 10% 프롤린(Sigma-aldrich)을 가한 후 잔량의 댄실 클로라이드를 제거한 뒤 2.5㎖의 에틸 에테르(Samchun, Seoul, Korea)를 가하여 3분간 진탕한 후, 분리된 상등액을 취하여 증발시키고 남은 잔사를 0.5㎖의 아세토니트릴에 정용하여 0.45㎛의 시린지 필터(Sartorius)로 여과하여 분석에 사용하였다. 바이오제닉 아민 분석을 위한 기기 분석 조건은 양 등의 조건(Yang, H. J. et al., 2016. J. Life Sci. 26, 571-583)에 따라 분석하였다.
In order to investigate whether biogenetic amines were produced, each isolate was inoculated into MRS broth and cultured at 37 ° C in a suspension incubator (VS-1203P3V, Vision Scientific Co. Ltd., Daejeon, Korea) for 24 hours at 150 rpm , 1 ml of the preculture was inoculated into 9 ml of MRS liquid medium containing 0.1% histidine and tyrosine amino acids histamine and tyramine precursor amino acids and cultured at 150 rpm for 24 hours in a 37 ° C suspension incubator. The culture broth was centrifuged at 13,000 rpm for 30 minutes, and the supernatant was used as a sample for biogenic amine analysis. 0.5 ml of each of the sample solution and the standard solution was taken and then 0.25 ml of 1,7-diaminoheptane (Sigma-aldrich), 0.25 ml of saturated Na 2 CO 3 solution (Sigma-aldrich) Acetone (Sigma-aldrich) and 0.4 ml of dansyl chloride (Sigma-aldrich) were mixed and derivatized at 45 ° C for 1 hour. To the derivatized sample, 0.25 ml of 10% proline (Sigma-aldrich) was added, and the remaining dansyl chloride was removed. 2.5 ml of ethyl ether (Samchun, Seoul, Korea) was added and the mixture was shaken for 3 minutes. The residue was evaporated and the residue was taken up in 0.5 ml of acetonitrile and filtered through a 0.45 μm syringe filter (Sartorius) for analysis. Instrumental assay conditions for biogenetic amine analysis are given in Yang et al. (Yang, HJ et al., 2016. J. Life Sci. 26, 571-583).
6. 선별 균주의 동정 및 계통수(phylogenic tree) 작성6. Identification of selection strains and phylogenic tree creation
최종 선별 균주의 동정을 위하여 16S rRNA 유전자 분석을 실시하였다. 균주의 동정을 위하여 균체를 MRS 액체배지에 접종하여 37℃에서 24시간 배양한 후 원심분리하여 균체를 회수하고 ZR 균류/세균의 DNA 미니트렙 키트(Zymo Research Corp., CA., USA)를 이용하여 DNA를 추출하였다. 추출한 DNA는 유니버설 프라이머인 27F 및 1492R 프라이머로 합성하여 유전자 단편을 증폭시켰고(Jeong, S. J. et al., J. Korean Soc. Food Sci. Nutr., 43, 550-556), 증폭된 PCR 산물은 QIAquick PCR 정제 키트(QIAGEN)로 정제한 후 ㈜마크로젠에 의뢰하여 염기서열을 분석한 후, 결과를 NCBI(National Center for Biotechnology Information, Bethesda, MD, USA)의 BLAST를 사용하여 GeneBank에 등록된 염기서열과 상동성을 비교하였다. 염기서열은 ExTaxone-e 서버(http://www.eztaxon.org)를 통해 표준 균주의 염기서열(서열번호 1)을 확보하여 MEGA 6.0 프로그램(Kumar, S. et al., 2004. Briefings Bioinf., 5, 150-163)을 사용하여 염기서열 간 상호 비교 후 계통도를 작성하였다. 계통도는 인접-결합(Neighbor-joining) 알고리즘(Saitou, N. and Nei, M., 1987, Mol. Biol. Evol., 4, 406-425)을 사용하였으며, 1,000회 반복으로 부트스트랩핑(bootstrapping)하여 작성한 계통도의 견고성을 확인하였다.
16S rRNA gene analysis was performed to identify the final selection strains. In order to identify the strain, the cells were inoculated into the MRS liquid medium, cultured at 37 ° C for 24 hours, centrifuged to recover the cells, and the ZR fungus / microbial DNA microtrep kit (Zymo Research Corp., CA., USA) And DNA was extracted. The extracted DNA was synthesized with universal primers 27F and 1492R primers to amplify the gene fragment (Jeong, SJ et al., J. Korean Soc. Food Sci. Nutr., 43, 550-556) After purification by a PCR purification kit (QIAGEN), it was analyzed by the manufacturer of Macrogen, and the results were analyzed using the BLAST of NCBI (National Center for Biotechnology Information, Bethesda, Md., USA) The homology was compared. The nucleotide sequence can be obtained from the MEGA 6.0 program (Kumar, S. et al., 2004. Briefings Bioinf.) By securing the nucleotide sequence of the standard strain (SEQ ID NO: 1) through ExTaxone-e server (http://www.eztaxon.org). , 5, 150-163). The systematic diagram is shown in the Neighbor-joining algorithm (Saitou, N. and Nei, M., 1987, Mol. Biol. Evol. 4, 406-425) was used, and bootstrapping was performed 1000 times to confirm the robustness of the system.
7. API 7. API ZYM을ZYM 이용한 효소 활성 조사 Enzyme activity investigation
최종 선발한 균주의 효소 활성을 조사하기 위해, API ZYM 키트(bioMeriux Co., France)를 사용하여 알칼리성 인산가수분해효소(alkaline phosphatase) 외 18가지 효소 활성을 검사하였다. 최종 선발 균주를 MRS 고체배지에서 배양한 후 균체만을 회수하여 멸균수에 3회 세척한 후 멸균수에 현탁하여 시료를 준비하였다. 500㎕의 현탁액을 5㎖의 현탁 배지에 풀어준 후 Mcfarland(bioMerieux)로 탁도 5~6으로 조정하였다. 현택액을 ZYM 키트의 각 큐플에 접종하여 37℃에서 4시간 동안 배양한 후 표현 활성 증가와 용해를 도와주는 ZYM A 및 B 시약을 각각의 큐플에 한 방울씩 떨어뜨린 후 5분간 반응 후 색깔의 변화를 관찰하여 효소 활성 정도를 조사하였다. 색의 변화 정도에 따라 0~5까지의 값으로 표시하였으며, 0은 음성반응, 5 (=40 nanomoles)는 최대 강도의 반응이고 4~1은 각각 30, 20, 10 및 5 nmoles의 중간 값을 나타내며 3 이상일 경우 양성으로 판정하였다.
To investigate the enzymatic activity of the final selected strains, 18 enzymatic activities were examined by using API ZYM kit (bioMeriux Co., France) and alkaline phosphatase. After the final selection strain was cultured in MRS solid medium, only cells were recovered and washed three times in sterilized water, and suspended in sterilized water to prepare a sample. 500 [mu] l of the suspension was dissolved in 5 ml of suspension medium and then adjusted to a turbidity of 5-6 with McFarland (bioMerieux). The current solution was inoculated on each cube of the ZYM kit and incubated at 37 ° C for 4 hours. ZYM A and B reagents were added dropwise to each cuplet to increase the expression activity and dissolve. After 5 minutes of reaction, And the degree of enzyme activity was examined. According to the degree of change of color, 0 to 5 values are indicated, 0 is negative reaction, 5 (= 40 nanomoles) is the maximum intensity response, 4 ~ 1 are medium values of 30, 20, 10 and 5 nmoles And 3 cases were positive.
8. 8. 내산성Acid resistance , , 내담즙성My bile 및 내열성 분석 And heat resistance analysis
위산에 대한 저항성을 확인하기 위해 pH 2.0, 3.0, 4.0 및 5.0(in 0.1N HCl)로 조정한 MRS 액체배지에 균주(106 CFU/ml)를 접종하여 30분 정치 후 시료를 회수하여 생균수를 측정하였다. 생존율은 대조구와 비교하여 생균수가 증가한 실험구를 내산성을 가진 것으로 평가하였다. 내담즙성 평가는 옥스갈(Oxgall, Sigma-aldrich)을 0, 0.1, 0.3, 0.5 및 1.0%(w/v)의 농도로 첨가하여 제조한 MRS 액체배지에 유산균 배양액 1%(2.0×109 CFU/ml)를 접종한 후 37℃에서 6시간 동안 배양하여 내산성과 동일한 방법으로 균의 생존율을 측정하였다. 열에 대한 안전성은 30℃, 40℃, 50℃ 및 60℃로 유지된 MRS 액체배지에 일정량의 균주를 접종한 후 10분간 정치한 이후에 생존한 미생물 수를 계수하여 측정하였다.
To confirm the resistance to gastric acid, strains (10 6 CFU / ml) were inoculated into the MRS liquid medium adjusted to pH 2.0, 3.0, 4.0 and 5.0 (in 0.1 N HCl) and allowed to stand for 30 minutes. Were measured. The survival rate of the experimental group was higher than that of the control group. To evaluate the biliary properties, 1% (2 × 10 9) of the lactic acid bacteria culture was added to the MRS liquid medium prepared by adding Oxgall (Sigma-aldrich) at the concentrations of 0, 0.1, 0.3, 0.5 and 1.0% (w / v) CFU / ml) and incubated at 37 ° C for 6 hours. The survival rate of bacteria was measured by the same method as that of acid tolerance. The safety for heat was determined by counting the number of surviving microorganisms after inoculating a certain amount of strain into the MRS liquid medium maintained at 30 ° C, 40 ° C, 50 ° C and 60 ° C, and allowing to stand for 10 minutes.
9. 선별 균주의 항생제 감수성 측정9. Antimicrobial Susceptibility Measurement of Screening Strain
항생제 감수성 시험은 NCCLS(National Committee for Clinical Laboratory Standards)의 디스크 확산법(disk diffusion)으로 실시하였다. 사용한 항생제 디스크(BBL Sensi-disc, Becton Dickinson Co., USA)는 아미카신(amikacin, 30㎍, AN), 아목시실린/클라불란산(amoxicillin/clavulanic acid, 20㎍/10㎍, AMC), 암피실린(ampicillin, 10㎍, AM), 세팔로신(cephalothin, 30㎍, CF), 시프로플록사신(ciprofloxacin, 5㎍, CIP), 콜리스틴(colistin, 10㎍, CL), 독시사이클린(doxycycline, 30㎍, D), 에리스로마이신(erythromycin, 15㎍, E), 젠타마이신(gentamicin, 10㎍, GM), 린코마이신(lincomycin, 2㎍, L), 카나마이신(kanamycin, 30㎍, K), 네오마이신(neomycin, 30㎍,, N), 노르플록사신(norfloxacin, 10㎍, NOR), 스트렙토마이신(streptomycin, 10㎍, S), 테트라사이클린(tetracycline, 30㎍, TE), 트리메토프림/설파메톡사졸(trimethoprim/sulfamethoxazole, 1.25㎍/23.75㎍, SXT)로 총 16종을 사용하였다. 감수성 시험 방법은 균주를 물러-힌트 액체배지(Merck, Germany)에 접종하고 37℃에서 5시간 동안 배양한 후 Macfarland(bioMerieux) No. 0.5로 탁도를 맞춘 후 물러-힌트 아가(Difco)에 도말하여 30분간 건조시킨 후 상기 16종의 항생제 디스크를 놓은 후 37℃에서 24시간 동안 배양하였다. 배양이 종료된 후 각 항생제에 대한 억제환의 크기를 측정하고 CLSI 가이드라인에 의해 감수성과 내성을 판정하였다.
Antibiotic susceptibility testing was performed by disk diffusion of the National Committee for Clinical Laboratory Standards (NCCLS). Amikacin (30 μg, AN), amoxicillin / clavulanic acid (20 μg / 10 μg, AMC), ampicillin (Becton Dickinson Co., USA) 10 μg of AM), cephalothin (30 μg of CF), ciprofloxacin (5 μg of CIP), colistin (10 μg of CL), doxycycline ), Erythromycin (15 g, E), gentamicin (10 g, GM), lincomycin (2 g, L), kanamycin (30 g, K), neomycin Streptomycin, 10 μg, S), tetracycline (30 μg, TE), trimethoprim / sulfamethoxazole (trimethoprim) / sulfamethoxazole, 1.25 / / 23.75,, SXT). For the susceptibility test, the strain was inoculated into a Leek-hint liquid medium (Merck, Germany) and incubated at 37 ° C for 5 hours. 0.5, dried on a Muller hint agar (Difco), and dried for 30 minutes. The 16 antibiotic disks were then placed and cultured at 37 ° C for 24 hours. After the culture was completed, the size of inhibitory rings for each antibiotic was measured and sensitivity and tolerance were determined by CLSI guideline.
10. 10. 프리바이오틱스Prebiotics 기질 이용 능력 Ability to use substrate
최종 선별 균주의 프리바이오틱스 기질 사용 능력은 앤 등의 방법(Ann, E. Y. et al., 2007. Int. J. Food Sci. Technol., 42, 411-419)을 일부 변형하여 측정하였다. 프리바이오틱스 기질로는 글루코오스(glucose), 자일리톨(xylitol), D-타가토오스(D-Tagatose), 이눌린(inulin), 락티톨(lactitol), 락툴로오스(lactulose), 프락토올리고당(fructooligosaccharide, FOS) 및 갈락토올리고당(galactooligosaccharide, GOS)으로 총 8종을 사용하였으며, 96-웰 플레이트를 이용하여 프리바이오틱 최소배지(0.5% 펩톤, 0.25% 아세트산나트륨, 0.05% 1M MgSO4·7H2O, 0.05 1M MgSO4·4H2O, 0.5% 트윈 80, 0.1% 디암모늄 시트르산, 0.1% 디포타슘 포스페이트 및 2% 프리바이오틱 기질)와 기질이 첨가되지 않은 배지에 선별 균주의 배양액을 1.0×106 CFU/ml가 되도록 접종한 다음 37℃에서 24시간 및 48시간 동안 배양한 배양액을 회수하여 600㎚에서 흡광도를 측정하여 기질 이용 능력을 측정하였다.
The prebiotics substrate capacity of the final screening strains was measured by the method of Ann et al., Ann. EY et al., 2007. Int. J. Food Sci. Technol., 42, 411-419. Examples of the prebiotics substrate include glucose, xylitol, D-tagatose, inulin, lactitol, lactulose, fructooligosaccharide, (0.5% peptone, 0.25% sodium acetate, 0.05% 1M MgSO 4 .7H 2 (0.5%), and the like) in a 96-well plate using a total of 8 kinds of microorganisms O, 0.05 1M MgSO 4 .4H 2 O, 0.5% Tween 80, 0.1% diammonium citrate, 0.1% dipotassium phosphate and 2% prebiotic substrate) and the medium to which the substrate was not added, 10 6 CFU / ml, cultured at 37 ° C for 24 hours and 48 hours, and the absorbance was measured at 600 nm to measure the substrate utilization ability.
실시예Example 1. 미생물의 분리 1. Isolation of microorganisms
프로바이오틱스 유산균의 분리를 위해 전라북도 순창군에서 재배된 베리류(블루베리, 복분자, 오디 및 아로니아) 생과와 베리류를 전통적인 방법으로 발효시켜 제조된 식초 및 엑기스 48종을 수집하였다. 수집한 시료는 단계 희석법을 이용하여 유산균 선택 배지에 배양하고 육안으로 집락의 형태, 색 등의 형태적 특징에 따라 42종의 분리주를 확보하였다.
For the isolation of probiotic Lactobacillus, 48 kinds of vinegar and extracts were prepared by fermenting berries (blueberry, bokbunja, audi and aronia) cultivated in Sunchang - gun, Jeollabuk - do with traditional methods. The collected samples were cultured in lactic acid bacteria selective medium using the stepwise dilution method and 42 kinds of isolates were obtained with the naked eye according to the morphological characteristics such as the shape and color of the colonies.
실시예Example 2. 분리주의 2. Removing Attention 세포외Extracellular 효소 활성 Enzyme activity
일반적으로 유산균은 종류에 따라 엔도펩티다제(endopeptidase), 아미노펩티다제(aminopeptidase), 디펩티다제(dipeptidase) 등 다양한 종류의 프로테아제(protease)를 생산하여 발효식품에서 구수한 맛 성분인 유리 아미노산의 함량에 영향을 주며, 특히 발효 중 프로테아제 이외에도 아밀라아제(amylase), 셀룰라아제(cellulase) 등과 같은 다양한 효소를 생성하여 식품의 풍미 및 조직감뿐만 아니라 다양한 기능성을 갖는 2차 산물이 생성된다고 알려져 있다(Law, J. and Haandrikman, A., 1997, Int. Dairy J. 7, 1-11). 따라서 앞서 선별한 42종의 분리주를 대상으로 프로테아제, 셀룰라아제 및 β-글루코시다제 3종에 대한 세포외 효소 활성을 측정한 결과, 9종의 분리주에서 프로테아제, 셀룰라아제 및 β-글루코시다제 3가지 효소를 생성하는 것을 확인하였다(표 1). 특히, 비배당체의 형성과 이소플라본 배당체의 가수분해에 필요한 촉매작용을 한다고 보고된 β-글루코시다제에 대하여 활성을 갖고 있어(Esaki, H. et al., 2004. J. Jpn. Soc. Food Sci. Technol., 51, 47-53), 전통발효식품에 주로 존재하는 대두 이소플라본 배당체인 제니스틴 및 다이드진의 체내 흡수를 위해 비배당체 형태로 전환하는 생물 전환 공정에 활용가능성을 갖는 β-글루코시다제 활성이 우수한 SBB07, SBB11 및 SOD62 분리주를 선별하였다.Generally, lactic acid bacteria produce various kinds of protease such as endopeptidase, aminopeptidase and dipeptidase according to the kind of free amino acid, which is a flavor ingredient in fermented foods. It is known that a secondary product having diverse functions as well as flavor and texture of food is produced by producing various enzymes such as amylase and cellulase in addition to protease during fermentation (Law, J and Haandrikman, A., 1997, Int. Dairy J. 7, 1-11). As a result of measuring the extracellular enzyme activities of protease, cellulase and β-glucosidase in the 42 isolates selected from the above, it was found that the protease, the cellulase and the β-glucoside three enzymes (Table 1). In particular, it has activity against β-glucosidase reported to catalyze the formation of non-glycosides and hydrolysis of isoflavone glycosides (Esaki, H. et al., 2004. J. Jpn. Soc. Food Sci. Technol., 51, 47-53), β-glucosyltransferase (β-glucosyltransferase), which has potential to be used in the bioconversion process to convert non-glycosyltransferable forms of soybean isoflavone glycosides, genistin and daidzin, SBB07, SBB11 and SOD62 isolates with excellent cytidase activity were selected.
a클리어존 크기(직경, mm)
a Clear zone size (diameter, mm)
실시예Example 3. 식품유해미생물에 대한 항균 활성 측정 3. Measurement of antimicrobial activity against food harmful microorganisms
유산균은 발효 중 생산하는 각종 유기산에 의해 식중독 원인균 및 부패 세균과 같은 유해미생물의 증식을 억제하고, 식품의 저장성을 높여주기 때문에 항균 활성이 있는 유산균 및 이를 이용한 식품 제조에 대한 연구가 많이 이루어지고 있다(Lim, S. M. et al., 2014. Kor. J. Microbiol., 50, 334-344). 식품유해미생물에 대한 항균 활성은 앞서 효소활성 측정을 통하여 선별한 1차 분리주 9종을 대상으로 바실러스 세레우스에 대하여 항균 활성을 조사하였다. 바실러스 세레우스 KCTC 3624 및 KCCM 40935으로 2종에 대하여 항균 활성을 측정한 결과, 9종의 선별 균주 모두 유해미생물에 대하여 항균 활성을 갖고 있었으며(데이터 미제시), 분리주 중에서도 SBB07, SBB11, SBBJ43, SBBJ56 및 SOD62 5종이 바실러스 세레우스 KCTC 3624 및 KCCM 40935에 대하여 우수한 항균 활성을 지니고 있었다(표 2). 따라서 앞서 선별한 9종의 분리주는 식품유해미생물에 대해 항균 활성을 모두 지니므로 식품 내의 부패균의 증식을 억제하여 식품 보존 및 유통과정에서의 산업적 적용이 가능한 분리주로 활용성이 높음을 확인하였다. Lactic acid bacteria inhibit the growth of harmful microorganisms such as food poisoning causative bacteria and spoilage bacteria by various organic acids produced during fermentation and increase the storage stability of foods, so that there are many studies on the production of lactic acid bacteria having antimicrobial activity and foods using them (Lim, SM et al., 2014. Kor J. Microbiol., 50, 334-344). Antimicrobial activity against food harmful microorganisms was investigated in nine primary isolates selected by enzyme activity measurement. Among the isolates, SBB07, SBB11, SBBJ43, and SBBJ56 were found to have antimicrobial activity against the harmful microorganisms when the antibacterial activity of Bacillus cereus KCTC 3624 and KCCM 40935 was measured. And
a클리어존 크기(직경, mm)
a Clear zone size (diameter, mm)
실시예Example 4. 항산화 활성 4. Antioxidant activity
상기 세포외 효소 활성 및 항균 활성 측정 실험을 통해 선발된 5종의 분리주를 대상으로 DPPH에 의한 자유 라디칼 제거 효과를 측정하는 방법으로 항산화 활성을 조사하였다. DPPH는 항산화 활성을 측정하기 위한 대표적인 기질로 페놀성 물질에 대한 항산화 작용의 지표 중 하나이며, 항산화제는 식용 유지나 지방질 식품의 가공 및 저장 중에 산화로 산패, 냄새, 풍미의 변화 및 변색의 방지를 위해 자유 라디칼에 전자를 공여하는 식품 내 지방질 산화를 억제하고(Jang, J. K. and Han, J. Y., 2002. Korean J. Food Sci. Technol., 34, 524-528), 인체 내 산소 자유 라디칼 반응이 생체 조직의 노화나 질병에 영향을 미치며 다양한 페놀성 물질들은 이러한 자유 라디칼 소거능이 우수하여 노화나 질병 예방하는데 중요한 역할을 한다(Park, C. K. et al., 2000. J. Korean Soc. Food Sci. Nutr., 29, 518-524). 따라서 DPPH를 이용하여 분리주의 항산화 활성을 측정한 결과, 선별 균주 중 SBB07, SBBJ56 및 SBBJ62 분리주가 15% 이상의 DPPH 활성을 나타냈으며, 특히 SBB07 분리주가 24.25%로 가장 높은 항산화 활성을 나타내었다(도 1).
The antioxidant activity of 5 different isolates selected from the extracellular enzyme activity and antimicrobial activities was determined by measuring the free radical scavenging effect by DPPH. DPPH is one of the indicators of antioxidant activity against phenolic substances as a representative substrate for measuring antioxidant activity, and antioxidants are used to prevent oxidative degradation, odor, change of flavor and discoloration during processing and storage of edible oils and fats (Jang, JK and Han, JY, 2002. Korean J. Food Sci. Technol., 34, 524-528), the oxygen free radical reaction in the human body inhibits the lipid oxidation The effects of various phenolic substances on the aging and disease of tissues are excellent because of their excellent free radical scavenging ability (Park, CK et al., 2000. J. Korean Soc. Food Sci. Nutr. , 29, 518-524). As a result, DPPH activity was measured using DPPH. As a result, DPPH activity of SBB07, SBBJ56 and SBBJ62 isolates showed 15% or more, and SBV07 isolate showed the highest antioxidative activity (Figure 1 ).
실시예Example 5. 5. 바이오제닉Biogenic 아민Amine 생성 확인 Confirm creation
바이오제닉 아민은 주로 단백질 함유량이 높은 국내 전통 식품이 발효 및 숙성되거나 부패되는 과정에서 아미노산의 탈탄산 반응에 의해 생성되거나 탈탄산효소활성을 갖는 미생물에 의해 생성된다. 특히, 히스타민과 티라민은 사람이 섭취 시 알레르기를 유발시키거나 혈압상승 및 두통을 일으킬 수도 있어(Yang, H. J. et al., 2016. J. Life Sci. 26, 571-583), 식품 안전성 측면에서 바이오제닉 아민에 대한 조사가 매우 중요하다. 따라서 선별 분리주를 대상으로 전구체 히스티딘과 티로신이 포함된 액체 배지에 선별 균주 5종을 접종 및 배양하여 분리주가 생성한 히스타민 및 티라민의 함량을 HPLC로 측정하였다. 그 결과, 하기 표 3에 개시한 바와 같이 SBB11, SBBJ56 및 SOD62 분리주에서는 바이오제닉 아민이 검출은 되었지만 정량이 되지 않는 매우 낮은 수치를 나타내었고, SBB07 및 SBBJ43 분리주에서는 히스타민과 티라민이 모두 검출되지 않은 것을 확인하였다. 식품 내의 히스타민 및 티라민은 약 100㎎ 이상을 섭취해야 중독 증상을 일으킬 수 있다고 보고되고 있어, 정량은 되지 않았지만 검출이 된 3종의 분리주도 모두 유해한 수준은 아님을 확인하였다. 따라서 선별한 균주 5종을 대상으로 효소 활성, 항균 활성 및 항산화 활성 측정 결과와 바이오제닉 아민 분석결과를 비교하였을 때, SBB07 분리주의 활성이 가장 우수하고 다양한 식품 분야에 적용이 가능하기 때문에 최종 선별 균주로 SBB07 분리주를 선택하였다. Biogenic amines are mainly produced by microorganisms that are produced by decarboxylation of amino acids or have decarboxylase activity during the fermentation, aging, or decay of domestic traditional foods with high protein content. In particular, histamine and tyramine may induce allergies or hypertension and headaches in human intake (Yang, HJ et al., 2016. J. Life Sci. 26, 571-583) Research on genic amines is very important. Therefore, the amount of histamine and tyramine produced by the isolate strain was measured by HPLC by inoculating and
bN.D: 미검출 b ND: Not detected
cN.Q: 미정량
c NQ:
실시예Example 6. 최종 선별 균주의 동정 6. Identification of the final selection strains
최종 선별한 SBB07 균주의 16S rRNA 유전자 염기서열 분석 결과를 이용하여 BLAST 검색 결과, 락토바실러스 브레비스(Lactobacillus brevis)로 판명되었으며, Eztaxon 서버에서 표준 균주와 상동성을 비교 분석하였다. 서열 정렬(sequence alignment) 분석에 사용한 파라미터(parameter) 및 옵션(option) 값은 단백질 무게 매트릭스로 고넷 시리즈를 사용하였고, 갭 오프팅(gap opening) 15, 갭 익스텐션(gap extension) 6.66 및 딜레이 트랜지션 웨이트 0.5로 설정하였고, 갭 패널티 5, 케이-투플 사이즈 2, 탑 디아그널스 4 및 윈도우 사이즈 4로 설정하였다. 그 결과, 도 2에 개시한 바와 같이 SBB07 균주(1302bp)는 락토바실러스 브레비스(Lactobacillus brevis) ATCC 367(NC 008497) 균주와 99%의 상동성을 나타내었다. 염기서열을 이용하여 계통수(phylogenetic tree)를 작성하기 위해 진화 거리(evolutionary distances)의 추론은 MSL(maximum composite Likehood) 방법을 모델로 사용하였다. 최종적으로, 락토바실러스 브레비스(Lactobacillus brevis) SBB07로 명명하였고, SBB07 균주는 한국미생물보존센터(KCCM, Korean Culture Center of Microorganisms)에 락토바실러스 브레비스 KCCM 12102P로 기탁하였다.
The result of BLAST search was confirmed to be Lactobacillus brevis using the 16S rRNA gene sequence analysis result of SBB07 strain selected last time, and the homology with the standard strain was compared and analyzed in Eztaxon server. Parameter and option values used for sequence alignment analysis were Gonet series as the protein weight matrix and were used for
실시예Example 7. API 7. API ZYMZYM 키트를Kit 이용한 Used 락토바실러스Lactobacillus 브레비스Brevis SBB07SBB07 균주의 Strain 효소 활성Enzyme activity
일반적으로 유산균이 프로바이오틱스로 사용되기 위해서는 이들이 생산하는 효소 또한 매우 중요한 부분을 차지하고 있어 최종 선별한 SBB07 균주의 효소 생산 여부를 확인하기 위해 API ZYM 키트를 이용하여 조사하였다. 그 결과, 하기 표 4에 개시한 바와 같이 SBB07 균주는 10 nmole의 루신 아릴아미다제(leucine arylamidase), 발린 아릴아미다제(valine arylamidase) 및 시스틴 아릴아미다제(cystine arylamidase) 계열의 프로테아제 효소 활성을 나타내었고, 나프톨-AS-BI-포스포히드롤라아제(Naphthol-AS-BI-phosphohydrolase)의 경우, 30 nmole의 높은 활성을 나타내었으며, β-갈락토시다제(β-galactosidase)는 40 nmole 이상의 높은 활성을 나타내어 한국인이 갖고 있는 우유 중 락토오스에 의한 유당 불내증의 저하에 많은 도움이 될 것이다. 또한, 발암 효소로 알려진 β-글루쿠로니다제(β-glucuronidase)의 경우 벤조피렌과 같은 독성물질이 체내 들어왔을 때, 간에서 글루쿠론산(glucuronic acid)과 결합되어 그 독성이 증가하지만, 결합된 물질이 소장에서 담즙과 함께 장내 배설되어 장내 세균의 β-글루쿠로니다제에 의해 탈포합 되면 다시 독성이 생길 수 있기 때문에(Cole, C. B. et al., 1989. Microb. Ecol. Health Dis. 2, 223-225.), 프로바이오틱스 유산균으로 사용되기 위해서는 활성이 낮은 균주가 바람직하며, SBB07 균주의 경우 10 nmole 이하로 활성이 미약하여 프로바이오틱스 균주로 인한 발암 유발의 위험이 없음을 확인하였다.In order to use lactic acid bacteria as a probiotic, the enzymes produced by these bacteria are very important. In order to confirm the production of SBB07, the API ZYM kit was used. As a result, as shown in Table 4 below, the SBB07 strain exhibited a protease activity of 10 nmole of leucine arylamidase, valine arylamidase and cystine arylamidase In the case of Naphthol-AS-BI-phosphohydrolase, the activity of 30 nmole was high, while the content of β-galactosidase was higher than 40 nmole And it is very helpful to decrease the lactose intolerance caused by lactose in Korean milk. In the case of β-glucuronidase, which is known as a carcinogenic enzyme, when a toxic substance such as benzopyran enters the body, it is combined with glucuronic acid in the liver to increase its toxicity, (Cole, CB et al., 1989. Microb., Ecol. Health Dis., ≪ / RTI > 2, 223-225). In order to be used as a probiotic lactic acid bacterium, it is preferable that the strain is low in activity. In case of SBB07 strain, the activity is weak to 10 nmole or less, and thus it is confirmed that there is no risk of carcinogenesis caused by probiotic strain.
a0은 효소활성 없는 것을 나타내며 5, 10, 20, 30 및 40은 각각 가수분해된 기질(nanomoles)을 나타냄.
a 0 indicates no enzyme activity, and 5, 10, 20, 30, and 40 represent hydrolyzed substrates (nanomoles), respectively.
실시예Example 8. 8. 락토바실러스Lactobacillus 브레비스Brevis SBB07SBB07 균주의 Strain 내산성Acid resistance , , 내담즙성My bile 및 내열성 And heat resistance
유산균을 식품과 함께 섭취 시 프로바이오틱스로서의 효과를 나타내기 위해서는 소화액 수준인 pH 3 이하의 낮은 pH 조건과 장내 담즙산의 농도보다 고농도의 담즙산이 함유된 배지에서 생장할 수 있는 조건이 요구되어야 한다(Gilliland, S. E. and Speck, M. L., 1977. Appl. Environ. Microbiol., 33, 15-18.). 따라서 SBB07 균주의 내산성 및 내담즙성을 조사한 결과, 도 3에 개시한 바와 같이 초기 접종 균수와 비교하였을 때 pH 3까지는 전혀 영향을 받지 않았으며, pH 2에서 약 14%가 감소하였지만, 약 86%가 생육하였다. 또한, 인공 담즙에 대한 저항성은 장내 담즙 농도(0.3%)보다 높은 옥스갈(oxgall)이 0.5% 함유된 배지에서 약 54%, 1.0% 함유된 배지에서는 약 46%가 생육하여 내담즙성도 우수한 것을 확인하였으며, SBB07 균주의 내열성은 MRS 액체배지에 SBB07 균주를 접종한 후 30℃, 40℃, 50℃ 및 60℃에서 10분간 정치 후 생존하는 수를 측정한 결과, 60℃에서도 약 113% 생존율을 보여 매우 높은 내열성을 나타내었다. 결론적으로 SBB07 균주는 유산균 제제의 제품화에 가장 큰 문제점이 되는 안정성과 보존성이 우수하며, 이로 인해 급격한 활력 저하와 사멸률에 대해 유리한 프로바이오틱스 소재로 활용 가능함을 확인하였다.
In order to demonstrate the effect of lactic acid bacteria as a probiotics, it is necessary to have a low pH condition at pH 3, which is the level of digestive juices, and a condition capable of growing in medium containing bile acids at a higher concentration than intestinal bile acid concentration (Gilliland, SE and Speck, ML, 1977. Appl. Environ. Microbiol., 33, 15-18.). Therefore, as shown in FIG. 3, the SBB07 strain showed no significant effect on the acidity and biliary properties of the strains when compared to the initial inoculum number, and about 14% at
실시예Example 9. 9. 락토바실러스Lactobacillus 브레비스Brevis SBB07SBB07 균주의 항생제 내성 Antibiotic resistance of the strain
최종 선별 균주 SBB07에 대한 항생제 감수성을 조사한 결과, 아목시실린/클라불란산(Amocicillin/Clavulanic acid), 독시사이클린(doxycycline) 및 에리스로마이신(erythromycin)에 대하여 생육이 억제됨을 확인하였고, 아미카신(amikacin), 세팔로신(cephalothin), 시프로플록사신(ciprofloxacin), 콜리스틴(colistin), 린코마이신(lincomycin), 카나마이신(kanamycin), 노르플록사신(norfloxacin), 스트렙토마이신(streptomycin), 테트라사이클린(tetracycline) 및 트리메토프림/설파메톡사졸(trimethoprim/sulfamethoxazole) 계열의 항생제에 대하여는 내성을 지니고 있음을 확인하였다(표 5). Antimicrobial susceptibility to the final strain SBB07 was examined and it was confirmed that the growth was suppressed against amoxicillin / clavulanic acid, doxycycline and erythromycin, and amikacin, But are not limited to, cephalothin, ciprofloxacin, colistin, lincomycin, kanamycin, norfloxacin, streptomycin, tetracycline, And antimicrobial resistance against trimethoprim / sulfamethoxazole (Table 5).
직경: cm, ND: 미검출, S: 1.2~1.5, SS: 1.6~2.0.
Diameter: cm, ND: Not detected, S: 1.2 to 1.5, SS: 1.6 to 2.0.
실시예Example 10. 10. 락토바실러스Lactobacillus 브레비스Brevis SBB07SBB07 균주의 Strain 프리바이오틱스Prebiotics 기질 이용 능력 Ability to use substrate
프리바이오틱스는 사람이나 동물에 의해 잘 소화되지 않는 난소화성 성분으로 프로바이오틱스 균주의 탄소원이 되어 장내 유익균의 생장을 선택적으로 촉진시켜 장내 환경을 개선하는데 도움을 주는 복합 당류로 알려져 있고, 대부분 탄수화물이나 식이섬유 형태로 존재하는 것으로 보고되고 있다(Roberfroid, M., 2007. J. Nutr., 137, 830S-837S). 최근 프로바이오틱스 균주와 프리바이오틱스를 함께 처리하는 신바이오틱스 제제가 개발되고 있는 추세로 기존 프로바이오틱스 균주를 활용한 제제와 비교해 증식 및 장내 정착 능력이 더욱 우수한 것으로 밝혀졌다(Ann, E. Y. et al., 2007. Int. J. Food Sci. Technol., 42, 411-419). 따라서 최종 선별 균주 SBB07의 프리바이오틱스 기질 이용 능력을 조사하기 위해, 프리바이오틱스 기질로, 글루코오스(glucose), 자일리톨(xylitol), D-타가토오스(D-Tagatose), 이눌린(inulin), 락티톨(lactitol), 락툴로오스(lactulose), 프락토올리고당(fructooligosaccharide, FOS) 및 갈락토올리고당(galactooligosaccharide, GOS)으로 8가지를 이용하여 24시간 동안 균주의 성장률을 측정하였다. 그 결과, 도 4에 개시한 바와 같이 GOS에서 글루코오스 대비 O.D 1.27로 가장 높은 성장률을 나타내었고, 다음으로 FOS 및 이눌린 순으로 높게 측정되었다. 락티톨, 락툴로오스, D-타가토오스 및 자일리톨에서는 O.D 0.4 이하로 낮은 성장률을 보였다(p<0.05). 결론적으로, 바이오제닉 아민을 생성하지 않는 SBB07 균주는 세포외 효소 및 항균 활성이 우수하며, 내담즙, 내산성, 내열성 및 항생제 내성을 지니고 있으며, GOS와 같은 프리바이오틱스 기질 이용 능력도 우수한 프로바이오틱스 소재로 활용 가능성이 높은 균주로 판단된다.
Prebiotics is an indigestible ingredient that is not digested well by humans or animals. It is known as a complex saccharide which helps improve the intestinal environment by selectively promoting the growth of beneficial bacteria in the intestines by becoming a carbon source of the probiotics strain. (Roberfroid, M., 2007. J. Nutr., 137, 830S-837S). Recently, a synbiotics preparation which treats probiotic strains and prebiotics together has been developed, and it has been found that the proliferation and intestinal colonization ability are superior to those using the existing probiotic strains (Ann, EY et al., 2007 Int. J. Food Sci. Technol., 42, 411-419). Therefore, in order to investigate the prebiotic substrate utilization ability of SBB07 as the final selection strain, glucose, xylitol, D-Tagatose, inulin, The growth rate of the strain was measured for 24 hours using 8 kinds of lactitol, lactulose, fructooligosaccharide (FOS) and galactooligosaccharide (GOS). As a result, as shown in Fig. 4, GOS showed the highest growth rate with respect to glucose at OD 1.27, followed by FOS and inulin, respectively. Lactitol, lactulose, D-tagatose, and xylitol showed a low growth rate of less than OD 0.4 (p <0.05). In conclusion, the SBB07 strain, which does not produce biogenic amines, has excellent extracellular enzymes and antimicrobial activity, is resistant to bile, acid, heat, and antibiotics, and is also a probiotic material with excellent prebiotic substrate utilization ability such as GOS It is considered to be a highly effective strain.
<110> Microbial Institute for Fermentation Industyry <120> Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, bile resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amine and uses thereof <130> PN17406 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 1291 <212> DNA <213> Lactobacillus brevis <400> 1 agtggcgaac tggtgagtaa cacgtgggaa atctgcccag aagcagggga taacacttgg 60 aaacaggtgc taataccgta taacaacaaa atccgcatgg attttgtttg aaaggtggct 120 tcggctatca cttctggatg atcccgcggc gtattagtta gttggtgagg taaaggccca 180 ccaagacgat gatacgtagc cgacctgaga gggtaatcgg ccacattggg actgagacac 240 ggcccaaact cctacgggag gcagcagtag ggaatcttcc acaatggacg aaagtctgat 300 ggagcaatgc cgcgtgagtg aagaagggtt tcggctcgta aaactctgtt gttaaagaag 360 aacacctttg agagtaactg ttcaagggtt gacggtattt aaccagaaag ccacggctaa 420 ctacgtgcca gcagccgcgg taatacgtag gtggcaagcg ttgtccggat ttattgggcg 480 taaagcgagc gcaggcggtt ttttaagtct gatgtgaaag ccttcggctt aaccggagaa 540 gtgcatcgga aactgggaga cttgagtgca gaagaggaca gtggaactcc atgtgtagcg 600 gtggaatgcg tagatatatg gaagaacacc agtggcgaag gcggctgtct agtctgtaac 660 tgacgctgag gctcgaaagc atgggtagcg aacaggatta gataccctgg tagtccatgc 720 cgtaaacgat gagtgctaag tgttggaggg tttccgccct tcagtgctgc agctaacgca 780 ttaagcactc cgcctgggga gtacgaccgc aaggttgaaa ctcaaaggaa ttgacggggg 840 cccgcacaag cggtggagca tgtggtttaa ttcgaagcta cgcgaagaac cttaccaggt 900 cttgacatct tctgccaatc ttagagataa gacgttccct tcggggacag aatgacaggt 960 ggtgcatggt tgtcgtcagc tcgtgtcgtg agatgttggg ttaagtcccg caacgagcgc 1020 aacccttatt atcagttgcc agcattcagt tgggcactct ggtgagactg ccggtgacaa 1080 accggaggaa ggtggggatg acgtcaaatc atcatgcccc ttatgacctg ggctacacac 1140 gtgctacaat ggacggtaca acgagtcgcg aagtcgtgag gctaagctaa tctcttaaag 1200 ccgttctcag ttcggattgt aggctgcaac tcgcctacat gaagttggaa tcgctagtaa 1260 tcgcggatca gcatgccgcg gtgaatacgt t 1291 <110> Microbial Institute for Fermentation Industyry <120> Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, even resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amines and uses thereof <130> PN17406 <160> 1 <170> KoPatentin 3.0 <210> 1 <211> 1291 <212> DNA <213> Lactobacillus brevis <400> 1 agtggcgaac tggtgagtaa cacgtgggaa atctgcccag aagcagggga taacacttgg 60 aaacaggtgc taataccgta taacaacaaa atccgcatgg attttgtttg aaaggtggct 120 tcggctatca cttctggatg atcccgcggc gtattagtta gttggtgagg taaaggccca 180 ccaagacgat gatacgtagc cgacctgaga gggtaatcgg ccacattggg actgagacac 240 ggcccaaact cctacgggag gcagcagtag ggaatcttcc acaatggacg aaagtctgat 300 ggagcaatgc cgcgtgagtg aagaagggtt tcggctcgta aaactctgtt gttaaagaag 360 aacacctttg agagtaactg ttcaagggtt gacggtattt aaccagaaag ccacggctaa 420 ctacgtgcca gcagccgcgg taatacgtag gtggcaagcg ttgtccggat ttattgggcg 480 taaagcgagc gcaggcggtt ttttaagtct gatgtgaaag ccttcggctt aaccggagaa 540 gtgcatcgga aactgggaga cttgagtgca gaagaggaca gtggaactcc atgtgtagcg 600 gtggaatgcg tagatatatg gaagaacacc agtggcgaag gcggctgtct agtctgtaac 660 tgacgctgag gctcgaaagc atgggtagcg aacaggatta gataccctgg tagtccatgc 720 cgtaaacgat gagtgctaag tgttggaggg tttccgccct tcagtgctgc agctaacgca 780 ttaagcactc cgcctgggga gtacgaccgc aaggttgaaa ctcaaaggaa ttgacggggg 840 cccgcacaag cggtggagca tgtggtttaa ttcgaagcta cgcgaagaac cttaccaggt 900 cttgacatct tctgccaatc ttagagataa gacgttccct tcggggacag aatgacaggt 960 ggtgcatggt tgtcgtcagc tcgtgtcgtg agatgttggg ttaagtcccg caacgagcgc 1020 aacccttatt atcagttgcc agcattcagt tgggcactct ggtgagactg ccggtgacaa 1080 accggaggaa ggtggggatg acgtcaaatc atcatgcccc ttatgacctg ggctacacac 1140 gtgctacaat ggacggtaca acgagtcgcg aagtcgtgag gctaagctaa tctcttaaag 1200 ccgttctcag ttcggattgt aggctgcaac tcgcctacat gaagttggaa tcgctagtaa 1260 tcgcggatca gcatgccgcg gtgaatacgt t 1291
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170152265A KR101960352B1 (en) | 2017-11-15 | 2017-11-15 | Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, bile resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amine and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170152265A KR101960352B1 (en) | 2017-11-15 | 2017-11-15 | Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, bile resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amine and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR101960352B1 true KR101960352B1 (en) | 2019-03-20 |
Family
ID=66036431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020170152265A KR101960352B1 (en) | 2017-11-15 | 2017-11-15 | Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, bile resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amine and uses thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101960352B1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110499271A (en) * | 2019-09-02 | 2019-11-26 | 千禾味业食品股份有限公司 | A kind of lactobacillus plantarum QR19 and its application |
KR20210022848A (en) * | 2019-08-21 | 2021-03-04 | 건국대학교 산학협력단 | NOVEL STRAIN OF Lactobacillus brevis AND COMPOSITION FOR ENHANCING IMMUNITY USING THE SAME |
CN114672386A (en) * | 2022-05-09 | 2022-06-28 | 武汉通元阁生物科技有限责任公司 | Lotus root yellow wine and brewing process thereof |
KR20230099810A (en) * | 2021-12-28 | 2023-07-05 | 롯데칠성음료주식회사 | Lactobacillus brevis Strain LRCC5229 suitable for functional fermented beverage and Use thereof |
KR102589192B1 (en) * | 2023-07-26 | 2023-10-16 | 재단법인 발효미생물산업진흥원 | Lactobacillus brevis SRCM 100917 strain having anti-inflammatory activity and probiotics property and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101589026B1 (en) * | 2014-09-26 | 2016-01-28 | 재단법인 발효미생물산업진흥원 | Bacillus subtilis SCJ1 strain not producing biogenic amine and having antimicrobial activity against pathogenic microorganism and uses thereof |
KR20170015688A (en) * | 2015-07-30 | 2017-02-09 | 재단법인 발효미생물산업진흥원 | - SCML458 Lactobacillus brevis SCML458 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce antibiotic resistance antioxidant activity -glucosidase and enzyme secretion activity and not producing biogenic amine and uses thereof |
KR20170015685A (en) * | 2015-07-30 | 2017-02-09 | 재단법인 발효미생물산업진흥원 | Bacillus subtilis SCM146 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce, antioxidant activity and enzyme secretion activity, and not producing biogenic amine and uses thereof |
KR20170015687A (en) * | 2015-07-30 | 2017-02-09 | 재단법인 발효미생물산업진흥원 | - SCML67 Lactobacillus brevis SCML67 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce antibiotic resistance antioxidant activity -glucosidase and enzyme secretion activity and not producing biogenic amine and uses thereof |
-
2017
- 2017-11-15 KR KR1020170152265A patent/KR101960352B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101589026B1 (en) * | 2014-09-26 | 2016-01-28 | 재단법인 발효미생물산업진흥원 | Bacillus subtilis SCJ1 strain not producing biogenic amine and having antimicrobial activity against pathogenic microorganism and uses thereof |
KR20170015688A (en) * | 2015-07-30 | 2017-02-09 | 재단법인 발효미생물산업진흥원 | - SCML458 Lactobacillus brevis SCML458 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce antibiotic resistance antioxidant activity -glucosidase and enzyme secretion activity and not producing biogenic amine and uses thereof |
KR20170015685A (en) * | 2015-07-30 | 2017-02-09 | 재단법인 발효미생물산업진흥원 | Bacillus subtilis SCM146 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce, antioxidant activity and enzyme secretion activity, and not producing biogenic amine and uses thereof |
KR20170015687A (en) * | 2015-07-30 | 2017-02-09 | 재단법인 발효미생물산업진흥원 | - SCML67 Lactobacillus brevis SCML67 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce antibiotic resistance antioxidant activity -glucosidase and enzyme secretion activity and not producing biogenic amine and uses thereof |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210022848A (en) * | 2019-08-21 | 2021-03-04 | 건국대학교 산학협력단 | NOVEL STRAIN OF Lactobacillus brevis AND COMPOSITION FOR ENHANCING IMMUNITY USING THE SAME |
KR102234569B1 (en) * | 2019-08-21 | 2021-03-30 | 건국대학교 산학협력단 | NOVEL STRAIN OF Lactobacillus brevis AND COMPOSITION FOR ENHANCING IMMUNITY USING THE SAME |
CN110499271A (en) * | 2019-09-02 | 2019-11-26 | 千禾味业食品股份有限公司 | A kind of lactobacillus plantarum QR19 and its application |
CN110499271B (en) * | 2019-09-02 | 2021-11-23 | 千禾味业食品股份有限公司 | Lactobacillus plantarum QR19 and application thereof |
KR20230099810A (en) * | 2021-12-28 | 2023-07-05 | 롯데칠성음료주식회사 | Lactobacillus brevis Strain LRCC5229 suitable for functional fermented beverage and Use thereof |
KR102633113B1 (en) | 2021-12-28 | 2024-02-05 | 롯데칠성음료주식회사 | Lactobacillus brevis Strain LRCC5229 suitable for functional fermented beverage and Use thereof |
CN114672386A (en) * | 2022-05-09 | 2022-06-28 | 武汉通元阁生物科技有限责任公司 | Lotus root yellow wine and brewing process thereof |
KR102589192B1 (en) * | 2023-07-26 | 2023-10-16 | 재단법인 발효미생물산업진흥원 | Lactobacillus brevis SRCM 100917 strain having anti-inflammatory activity and probiotics property and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101960352B1 (en) | Lactobacillus brevis SBB07 strain from fermented berry having antimicrobial activity against pathogenic microorganism, antibiotic resistance activity, antioxidant activity, enzyme secretion activity, acid resistance activity, bile resistance activity, heat resistance activity, prebiotics substrate availability and not producing biogenic amine and uses thereof | |
Aarti et al. | In vitro studies on probiotic and antioxidant properties of Lactobacillus brevis strain LAP2 isolated from Hentak, a fermented fish product of North-East India | |
KR101734367B1 (en) | - SCML67 Lactobacillus brevis SCML67 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce antibiotic resistance antioxidant activity -glucosidase and enzyme secretion activity and not producing biogenic amine and uses thereof | |
KR100911115B1 (en) | Novel lactic acid bacteria having acid resistance, bile-salt resistance and anti-bacterial effect and composition containing the same | |
EP2616558B1 (en) | Bacillus subtilis isolate from corn | |
KR101734368B1 (en) | - SCML458 Lactobacillus brevis SCML458 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce antibiotic resistance antioxidant activity -glucosidase and enzyme secretion activity and not producing biogenic amine and uses thereof | |
KR101734361B1 (en) | Bacillus subtilis SCM146 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce, antioxidant activity and enzyme secretion activity, and not producing biogenic amine and uses thereof | |
KR102001994B1 (en) | Pediococcus pentosaceus SRCM102736 strain having immunity activity, antiviral activity and probiotics properties and uses thereof | |
KR101485182B1 (en) | Novel Lactobacillus plantarum from kimchi with inhibiting activities on pathogenic microorganism and use thereof | |
KR101736324B1 (en) | Bacillus subtilis SCM121 strain from traditional soy sauce having antimicrobial activity against pathogenic microorganism of soy sauce, antioxidant activity and enzyme secretion activity, and not producing biogenic amine and uses thereof | |
KR101381547B1 (en) | Novel Leuconostoc mesenteroides from kimchi with inhibiting activities on pathogenic microorganism and use thereof | |
KR101993617B1 (en) | Lactobacillus pentosus SRCM101105 strain having antimicrobial activity and probiotics properties and uses thereof | |
KR101999531B1 (en) | Lactobacillus perolens SRCM102283 strain having immunity activity, antiviral activity and probiotics properties and uses thereof | |
KR101274467B1 (en) | Lactobacillus plantarum JBMI F5 strain having antibacterial activity against harmful bacteria and uses thereof | |
KR20190063795A (en) | Method for producing aronia fermentation product using Lactobacillus plantarum MIFI-SY3 strain | |
KR101498272B1 (en) | Bacillus subtilis strain isolated from Kimchi, producing antimicrobial substances and having immune activity, and probiotics composition using it | |
KR101996080B1 (en) | Lactobacillus plantarum SRCM101594 strain having antimicrobial activity and probiotics properties and uses thereof | |
KR102001990B1 (en) | Pediococcus acidilactici SRCM102615 strain having immunity activity, antiviral activity and probiotics properties and uses thereof | |
KR101960189B1 (en) | NOVEL STRAIN OF Lactobacillus plantarum AND USE THEREOF | |
KR101839372B1 (en) | Bacillus subtilis SCGB 634 strain having acid-resistance activity, bile acid-resistance activity, antioxidant activity and antimicrobial activity and not producing biogenic amine and secreting protease, cellulase and amylase and uses thereof | |
KR102001992B1 (en) | Pediococcus acidilactici SRCM102607 strain having immunity activity, antiviral activity and probiotics properties and uses thereof | |
KR102100377B1 (en) | Bacillus subtilis SRCM103571 strain having improved mucosal adhesive capacity, antioxidant activity, anti-aging activity and probiotics property and uses thereof | |
KR101811246B1 (en) | Bacillus subtilis SCGB 320 strain having acid-resistance activity, bile acid-resistance activity, antioxidant activity, lipase inhibition activity, fibrinolytic activity and antimicrobial activity and not producing biogenic amine and secreting protease and amylase and uses thereof | |
KR102159380B1 (en) | Bacillus amyloliquefaciens SRCM101439 strain having antioxidant activity and probiotics property and uses thereof | |
KR102010441B1 (en) | Lactobacillus plantarum SRCM101502 strain having antimicrobial activity and probiotics properties and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |